
ALT A webinar announcement for a pancreas cancer seminar titled "Cáncer de páncreas: Los tratamientos más recientes" on October 29 at 2:00 p.m. ET. The speakers include Arturo Loaiza-Bonilla, Catalina Fandiño, and Juan Pellerano-Rendón. Logos at the bottom include LetsWin, Nuestras Voces Adelante, and Novocure.

ALT Antigen sources and vaccine platforms in PDAC. Created in BioRender. Chap, B. S. (2026) https://BioRender.com/7xdlrqt. (A) Patient-derived tumour tissue can provide multiple antigen sources, including whole-tumour lysate, TAAs, TSAs, and neoantigens. These antigens undergo selection and, when applicable, computation epitope prediction to prioritise immunogenic targets, which are subsequently incorporated into a final vaccine formulation. (B) Several vaccine platforms are being explored in PDAC, including cell-based and dendritic cell-based vaccines, mRNA-based and DNA-based vaccines, peptide and protein vaccines, and microorganism-based approaches, all aiming to induce tumour-specific T-cell responses against the pancreatic tumour.

ALT Certainly. Here's a suitable alt text: A person in athletic wear smiles outdoors with the text: "Meet Bethany. Q: What keeps you motivated on the tough days? A: My Uncle Yale! After years of injuries, I never take for granted the ability to run and train." The image includes the logo for Team Let's Win Pancreatic Cancer.

ALT A person stands outdoors on a hill overlooking a marina. The text overlay reads: “The NYC Marathon has always been a bucket list item for me. I am so excited to run in one of my favorite cities, with my cousin, for my uncle, with our friends and family cheering us on.” —BETHANY HOLDEN. The image features logos for "Team Let’s Win" and "Pancreatic Cancer.”

ALT A webinar announcement for a pancreas cancer seminar titled "Cáncer de páncreas: Los tratamientos más recientes" on October 29 at 2:00 p.m. ET. The speakers include Arturo Loaiza-Bonilla, Catalina Fandiño, and Juan Pellerano-Rendón. Logos at the bottom include LetsWin, Nuestras Voces Adelante, and Novocure.













